š§¬ Tirzepatide ā Dual GIP/GLP-1 Receptor Agonist for Metabolic Research
Synonyms: LY3298176, Dual Incretin Analog
CAS Number: 2023788-19-2
Sequence: 39-amino acid linear peptide with C20 fatty diacid moiety
Molecular Weight: ~4813.5 Da
Form: Pre-filled 40mg injectable pen
Purity: ā„98% (HPLC)
Research Use Only. Not for human consumption.
---
Description:
Tirzepatide is a synthetic dual incretin receptor agonist that activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual engagement enhances insulin secretion, reduces appetite, and improves metabolic flexibility. The 40mg pre-filled pen format provides high-dose, once-weekly delivery, ideal for advanced metabolic research protocols requiring sustained incretin exposure.
---
āļø Mechanism of Action:
Tirzepatide mimics the bodyās natural incretin response to nutrient intake:
ā¢ GIPR Activation: Enhances insulin secretion, improves adipocyte insulin sensitivity, and increases adiponectin
ā¢ GLP-1R Activation: Delays gastric emptying, suppresses appetite, and reduces glucagon secretion
Together, these pathways produce synergistic effects on glucose regulation, body weight, and lipid metabolismāsurpassing the efficacy of GLP-1 agonists alone.
---
š Research Applications:
Tirzepatide is under investigation in preclinical and clinical models for:
ā¢ Obesity and body composition modulation
ā¢ Type 2 diabetes and insulin resistance
ā¢ Non-alcoholic fatty liver disease (NAFLD)
ā¢ Cardiometabolic risk reduction
ā¢ Neuroendocrine signaling and appetite regulation
In clinical trials, Tirzepatide has demonstrated up to 22.5% body weight reduction and superior glycemic control compared to semaglutide, with additional benefits in lipid and inflammatory markers.
---
š§Ŗ Dosing & Handling (Preclinical):
ā¢ Formulation: 40mg pre-filled pen
ā¢ Half-life: ~5 days (supports once-weekly administration)
ā¢ Storage: Refrigerate at 2ā8Ā°C; protect from light
ā¢ Administration: Subcutaneous injection; rotate sites weekly
ā¢ Cycle: 12ā72 weeks typical for metabolic remodeling studies
---
š¦ Packaging & Storage:
Supplied as a sterile, pre-filled 40mg pen for subcutaneous administration. Store refrigerated 2ā8Ā°C. Do not freeze. Use aseptic technique. For research use only.
SKU: TRZ-40MG-PEN-DSP
